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Regulation of chitinase-3-like-1 in T cell elicits Th1
and cytotoxic responses to inhibit lung metastasis
Do-Hyun Kim1,2, Hong-Jai Park3, Sangho Lim1,2, Ja-Hyun Koo1,2, Hong-Gyun Lee1,2, Jin Ouk Choi1, Ji Hoon Oh4,
Sang-Jun Ha4, Min-Jong Kang 5, Chang-Min Lee6, Chun Geun Lee 6,7, Jack A. Elias6,8 & Je-Min Choi1,2,9
Chitinase-3-like-1 (Chi3l1) is known to play a signiﬁcant role in the pathogenesis of Type 2
inﬂammation and cancer. However, the function of Chi3l1 in T cell and its clinical implications
are largely unknown. Here we show that Chi3l1 expression was increased in activated T cells,
especially in Th2 cells. In addition, Chi3l1-deﬁcient T cells are hyper-responsive to TcR
stimulation and are prone to differentiating into Th1 cells. Chi3l1-deﬁcient Th1 cells show
increased expression of anti-tumor immunity genes and decreased Th1 negative regulators.
Deletion of Chi3l1 in T cells in mice show reduced melanoma lung metastasis with increased
IFNγ and TNFα-producing T cells in the lung. Furthermore, silencing of Chi3l1 expression in
the lung using peptide-siRNA complex (dNP2-siChi3l1) efﬁciently inhibit lung metastasis with
enhanced Th1 and CTL responses. Collectively, this study demonstrates Chi3l1 is a regulator
of Th1 and CTL which could be a therapeutic target to enhance anti-tumor immunity.
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Chitinase is a defensive enzyme in plant to cleaves chitinand protects hosts against pathogens1–3. Chitinase-likeproteins (CLPs) are evolutionarily conserved in mammals
but do not have the enzymatic activity to directly degrade
chitin4,5. They have evolved to be important in the development
and progression of Th2 inﬂammation, parasitic infections, and
cancer6–11.
Ym-1, also called chitinase 3-like 3 (Chi3l3), and Ym-2, also
called chitinase 3-like 4 (Chi3l4), are CLPs that are important
contributors to Th2 inﬂammation in allergies7. A previous study
has demonstrated that Ym-1 and Ym-2 could increase the
number of γδ T cells and IL-17 production in a nematode
infection model9. This result demonstrates their evolutionarily
conserved roles as innate defense systems. Chitinase 3-like 1
(Chi3l1), also known as breast regression protein 39 (BRP-39),
has been more emphasized in cancer and lung inﬂammation due
to human homolog YKL-40, which is mainly expressed in breast
cancer cells and lung macrophages6,10–12. In Streptococcus
pneumoniae infections, Chi3l1 regulates macrophage cell death to
promote bacterial clearance, indicating a function in innate
immunity against pathogens13. Studies of transgenic mouse
models show that both BRP-39 and YKL-40 are critical regulators
of Th2 inﬂammation in the lung. OVA sensitization induces
Chi3l1 expression by macrophages, and induced asthmatic Th2
inﬂammation is markedly diminished in BRP-39-deﬁcient back-
ground, while lung speciﬁc YKL-40 overexpression rescues the
Th2 inﬂammation6. In addition, Chi3l1 deﬁciency signiﬁcantly
ameliorates IL-13-induced ﬁbrosis and IL-18-mediated IL-13
production, suggesting an essential role of Chi3l1 in the
pathogenesis of Th2 inﬂammation6,14.
Chi3l1 was recently found to be involved in pulmonary
metastasis10,11. The expression of Chi3l1 was signiﬁcantly
increased by melanoma tumor cell challenge and Chi3l1 deﬁ-
ciency reduced lung metastasis of melanoma or breast cancer
cells. Although studies have shown that Th2-driven inﬂammation
in the lung induces BRP-39 and it contributes to Th2
inﬂammation, ﬁbrosis, and tumors, the direct function of Chi3I1
in adaptive immunity such as T cell responses is totally unknown.
Th2 polarization and IL-4 have been shown to promote tumor
growth and metastasis15,16. Therefore, we hypothesized that
speciﬁc immune regulatory function of Chi3l1 that drive Th2
polarization while inhibiting Th1 activation may contribute to the
tumor development and progression. Here we demonstrated that
Chi3l1 expression was highly induced in activated T cells and Th2
cells. Chi3l1-deﬁcient T cells were differentiated into T cells with
Th1-prone phenotypes with hyper-responsive to IFNγ signaling
and melanoma lung metastasis was signiﬁcantly reduced in the
mice with both Chi3l1 total knock out and CD4−Cre system. In
addition, in vivo siRNA silencing of Chi3l1 with a cell-
penetrating peptide dNP2 efﬁciently inhibited melanoma lung
metastasis by increasing both Th1 and cytotoxic T-lymphocyte
(CTL) responses. When viewed in combination, these studies
suggest that Chi3l1 plays an essential role in regulation of Th1
and CTL differentiation. These studies highlight that speciﬁc
intervention of Chi3l1 in T cells could be an effective therapy of
pulmonary metastasis.
Results
Chi3l1 negatively regulates T cell activation. Previous studies
have reported that CLPs are highly expressed in lung tissue,
especially macrophages6,17. However, expression of CLPs in
lymphocytes, especially in T cells, has not been studied. We
performed comparative analysis of mRNA levels of Chi3l1,
Chitotriosidase, AMCase, and Ym-1 in splenic macrophages,
DCs, T cells, B cells, and NK cells (Supplementary Fig. 1). These
chitinases and CLPs were highly expressed in macrophages
however the expression of Chi3l1 was most prominent among
these chitinases and CLPs in CD4 and CD8 T cells. In addition,
we examined chitinase and CLP expression in naïve and activated
CD4 and CD8 T cells. Both mRNA (Fig. 1a, b) and protein
(Fig. 1c, d) level of Chi3l1 was strongly induced time dependently
upon anti-CD3 and anti-CD28 stimulation. In addition, Chi3l1
expression was strongly induced in Th0 and Th2 cells compare to
the other effector T cell subsets (Fig. 1e), suggesting a potential
role of Chi3l1 during T cell activation and differentiation. On the
other hand, no signiﬁcant abnormalities were noted in immune
cells development between WT and Chi3l1 knock out (KO) mice
(Supplementary Fig. 2). To investigate whether Chi3l1 is a
negative regulator of T cell activation, MACS-puriﬁed naïve CD4
and FACS-puriﬁed CD8 T cells from wild type (WT) and Chi3l1
KO mouse splenocytes were activated by anti-CD3 and anti-
CD28 antibodies for 3 days. Cytokine ﬂow cytometric analysis
demonstrated that Chi3l1 deﬁciency in both CD4 and CD8 T cells
signiﬁcantly increased IFNγ production, while IL-4 production
decreased (Fig. 2a, b). ELISA analysis of Chi3l1 KO CD4 T cells
showed increase of both IFNγ and IL-2, decrease of IL-4, and no
difference was seen in IL-17 (Fig. 2c) suggesting Th1-like char-
acter. In addition, there was increased IFNγ and TNFα expression
in Chi3l1 KO CD8 T cells (Fig. 2d), suggesting that Chi3l1
negatively regulates T cell activation, especially regulates Th1 or
CTL cytokine production. Because IL-2 and IFNγ are important
cytokines for T cell proliferation, we conﬁrmed the proliferation
properties of Chi3l1 KO T cells compared to wild type. CFSE-
labeled Chi3l1 KO CD4 T cells showed a higher proportion of
divided cells in response to TcR stimuli compared to control
T cells (Fig. 2e, f). In addition, phosphorylation of Akt, Erk,
STAT1, and STAT5 was increased in Chi3l1 KO T cells, sug-
gesting that Chi3l1 is an important factor for regulating T cell
proliferation (Fig. 2g, h). Collectively, these results demonstrate
that Chi3l1 is expressed in T cells and regulate T cell activation
and proliferation for controlling effector functions.
Chi3l1 inhibits Th1 differentiation via IFNγ-STAT1 axis.
Because Chi3l1 expression was the most signiﬁcant in Th2 cells
and its deﬁciency in T cells led to increased IL-2 and IFNγ, but
decreased IL-4, we hypothesized that it regulates effector T cell
differentiation between Th1 and Th2. To investigate whether
Chi3l1 regulates Th1 and Th2 differentiation, MACS-sorted CD4
+CD62LhighCD44low WT and Chi3l1 KO naïve CD4 T cells were
differentiated into Th1, 2, and Th17 cells under speciﬁc skewing
conditions. The proportion of IFNγ-producing cells signiﬁcantly
increased not only in Th1 but also in Th2 and Th17 conditions
while IL-4 in Th2 was decreased and showed no difference in
Th17 (Fig. 3a, b). Accumulated cytokines in supernatants showed
equivalent patterns (Fig. 3c). T-bet, Runx3, and Eomes, which are
important transcription factors of Th1 differentiation, increased
in Chi3l1-deﬁcient Th1 cells with increased IFNγ and GM-CSF.
JunB, which is important for IL-4-related Th2 differentiation, was
signiﬁcantly reduced, and no differences were observed in Th17-
related factors (Fig. 3d). In Chi3l1-deﬁcient Th1 cells, the level of
phosphorylated STAT1 was signiﬁcantly increased, with no dif-
ference in the level of phosphorylated STAT4 suggesting Chi3l1
regulates IFNγ signaling not IL-12 (Fig. 4a). On the other hand,
phosphorylated STAT6 level was signiﬁcantly reduced in Th2,
collectively suggesting that Chi3l1 could be a negative regulator of
IFNγ signaling to commit T cells to more like Th2 cells. In
addition, the proportion of IFNγ-producing cells was signiﬁcantly
decreased by IFNγ-neutralizing antibody in Chi3l1 KO Th1 cells
(Fig. 4b, c). At 20 μg/mL neutralizing antibody, IFNγ-producing
cells were equivalent in WT and Chi3l1 KO Th1 cells. We also
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treated recombinant IFNγ cytokine to WT and Chi3l1 KO naïve
CD4 T cells that Chi3l1 KO T cells showed signiﬁcantly increased
pSTAT1 level compared to WT T cells (Fig. 4d) suggests that
increased IFNγ production by Chi3l1 deﬁciency in T cells could
be dependent on increased IFNγ-STAT1 signaling. In addition,
we conﬁrmed IFNγ dependency in CD8 T cells, and found that
IFNγ and Granzyme B producing activated Chi3l1 KO CD8
T cells were decreased by neutralizing IFNγ antibody treatment,
and the level was equivalent with that in WT T cells at 20 μg/mL
IFNγ neutralizing antibody (Fig. 4e, f). Taken together, these
results demonstrate that Chi3l1 negatively regulates Th1 or CD8
effector T cell differentiation by inhibiting IFNγ-mediated STAT1
phosphorylation.
Chi3l1 suppresses Th1-related and tumoricidal genes. To
investigate how Chi3l1 regulates the IFNγ-mediated signaling
pathway, we isolated RNA from WT and Chi3l1 KO naïve CD4
T cells and differentiated Th1 cells. The transcriptomes of WT
and Chi3l1 KO, naïve, and Th1 cells were analyzed by RNA
sequencing. To determine the differences in gene expression
between WT and Chi3l1 KO Th1 cells, we classiﬁed genes that
were highly expressed in Th1 cells compared with naïve T cells.
We also classiﬁed genes that were differently expressed in Chi3l1
KO Th1 cells compared to WT Th1 cells (Fig. 5a). We found 31
up-regulated genes and 72 down-regulated genes in Chi3l1 KO
Th1 cells compared to WT Th1 cells. A heatmap obtained by
clustering methods showed decreased twist1 and socs1, which are
IFNγ-regulatory genes, and increased ifng, ctse, cxcr2, and tnfsf10
(as known as TRAIL), which are tumoricidal molecules, in Chi3l1
KO Th1 cells (Fig. 5b). A scatterplot summarized these patterns
(Fig. 5c). To conﬁrm the RNA-sequencing results, we performed
quantitative RT-PCR analysis of WT and Chi3l1 KO Th1 cells
(Fig. 5d). Expression of SOCS1, a phosphatase that inhibits
phosphorylation of STAT1, was signiﬁcantly decreased without
differences in SOCS3 and SOCS5 in Chi3l1-deﬁcient Th1 cells
compared to WT Th1 cells. Twist1, a Th1 inhibitory molecule,
was also reduced, presumably explaining how Chi3l1 KO
Th1 cells produce more CTSE, TRAIL, IFNγ, and CXCR2. The
molecular expression patterns were the same in CD8 T cells
(Fig. 5e). In addition, activated Chi3l1 KO CD8 T cells expressed
higher levels of T-bet, IFNγ, Perforin, and Granzyme B, sug-
gesting that Chi3l1 KO CD8 T cells induce high levels of effector
molecules related to CTL function. Taken together, these results
suggest Chi3l1 is a negative regulator of gene expressions
regarding Th1 and CTL functions.
Chi3l1 deﬁciency in T cells inhibits pulmonary metastasis. The
increase of effector functional molecules in Chi3l1-deﬁcient
T cells prompted us to investigate whether Chi3l1-deﬁcient Th1
and CTL contributed to anti-tumor immunity. To test our
hypothesis, we utilized B16F10 melanoma lung metastasis model.
At 14 days from intravenous injection of 5 × 105 B16F10 mela-
noma cells into WT and Chi3l1 KO mice, metastatic melanoma
colonies were observed on the lung surface (Fig. 6a). Melanoma
lung metastasis was signiﬁcantly reduced in the Chi3l1 KO mice
compared to WT animals (Fig. 6b). Histological analysis of
sectioned slides revealed that inﬁltrated tumors around blood
vessels were also signiﬁcantly decreased in Chi3l1 KO mice
(Fig. 6c). Increased inﬁltration of IFNγ-producing CD4 T cells
and CD8 T cells was signiﬁcantly higher in the lungs of Chi3l1
KO mice than WT animals (Fig. 6d, e). However no difference
was observed in the IFNγ-producing properties of NK cells or
non-lymphocytic populations (Fig. 6f, g). Consistent with the
RNA-sequencing and RT-PCR results, Chi3l1 KO mice had
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Fig. 1 Chitinase and Chitinase-like protein expressions in T cells. a, b mRNA expression of chitinase (Chitotriosidase, AMCase) and chitinase-like protein
(Chi3l1, Ym-1) in mouse CD4 and CD8 T cells upon anti-CD3 and anti-CD28 stimulation for 3 days. Each gene expression level was normalized to β-actin,
and represented as fold change to Non-activated (NA). c, d Chi3l1 protein level in CD4 and CD8 T cells stimulated by plate-bound anti-CD3 and anti-CD28
antibodies for indicated time point. Densitometric values of band intensity were calculated by normalization to the value of β-actin. e Chi3l1 mRNA
expression in naïve and effector T cell subsets. Chi3l1 mRNA expression level was normalized to β-actin level. Data are mean± SD of three sets of
independent experiments (n= 6). n.d., not detected; **p< 0.01, ***p< 0.001 (two-tailed Student’s t-test)
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increased mRNA for anti-tumor immunity molecules including
CTSE, TRAL, IFNγ, T-bet, Perforin, and Granzyme B, while the
expression of Th1-inhibitory molecules such as Twist1 and
SOCS1 was signiﬁcantly reduced (Fig. 6h). To conﬁrm the
increased tumoricidal activity in Chi3l1 KO CD8 T cells, we
performed co-culturing experiments with pre-activated WT or
Chi3l1 KO CD8 T cells and B16F10 melanoma cells. Chi3l1 KO
CD8 T cells showed more potent tumor-killing activity than WT
CD8 T cells (Fig. 6i). However, no signiﬁcant difference in the
cytotoxicity of WT and Chi3l1 KO NK cells was observed
(Fig. 6j). This result suggest reduction of melanoma lung
metastasis would be mainly dependent on altered T cell respon-
ses. To further conﬁrm the question whether inhibition of
pulmonary metastasis is truly depending on altering T cell
functions, we generated CD4 speciﬁc Chi3l1 KO mice by crossing
CD4-Cre and Chi3l1 ﬂoxed mice (Fig. 7a). At 14 days from
melanoma tumor cell injection, as consistent, we found sig-
niﬁcantly decreased number of pleural colonies in the lung of
CD4-Chi3l1 KO mice (Fig. 7b, c) with reduced tumor inﬁltration
around the vessel (Fig. 7d). There are signiﬁcantly increased IFNγ
and TNFα expressing both CD4 and CD8 T cells (Fig. 7e, f), while
there are no differences in NK cells and non-lymphocytic
populations in CD4-Chi3l1 KO mice (Fig. 7g, h). Very con-
sistently, there are elevated anti-tumor molecules such as per-
forin, granzyme B, CTSE and increased Th1 transcription factor
T-bet while decrease of Th1 inhibitory molecule like SOCS1 and
Twist1 in the lung of CD4-Chi3l1 KO mice (Fig. 7i). Importantly
we further conﬁrmed that there were signiﬁcantly increased
tumor inﬁltrating lymphocyte (TIL) populations in the lung by
CD45 staining which contains IFNγ producing T cells with
increased Th1 and CTL related mRNA expression in tumor
region. Although there is no signiﬁcance of statistical analysis due
to the limited number of samples, CD8/Treg ratio showed
increased pattern in CD4-Chi3l1 KO mice, which is clinically
critical value for successful immunotherapy18,19 (Supplementary
Fig. 3). However, IFNγ producing T cells from spleen and
inguinal lymph node was not increased (Supplementary Fig. 4),
suggesting elevated antigen speciﬁc T cell recruitment and
actions. Furthermore, we transferred WT or Chi3l1 KO Th1 and
activated CD8 T cells into RAG KO mice consistently shows that
Chi3l1 KO T cell transfer shows more signiﬁcantly reduced lung
metastasis of melanoma cells compare to WT T cell transfer
(Supplementary Fig. 5) suggesting the total KO and CD4-Chi3l1
KO mice phenotype of reduced lung metastasis would be due to
altered intrinsic T cell functions. Collectively, these results suggest
that Chi3l1 is a negative regulator of Th1 and CTL responses to
enhance pulmonary metastasis.
Targeted silencing of Chi3l1 by peptide-siRNA complex. Pre-
viously, we reported a novel cell-penetrating peptide (CPP),
dNP2, which delivers an immune regulatory protein into T cells
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and showed its therapeutic potential in autoimmune diseases20,21
We hypothesized that introducing siRNA against Chi3l1
(siChi3l1) via dNP2 peptide would be a novel strategy and could
enhance anti-tumor immunity to reject tumors. We utilized
chemically synthesized dNP2 peptide combined with HA2 for
helping endosomal escape22 for making noncovalent peptide-
siRNA complex based on N/P ratio, which refers the number of
amine group in dNP2-HA2 to the number of phosphate group in
siRNA (Fig. 8a). 30 min incubation at room temperature of the
complex was analyzed by gel retardation assay that dNP2-HA2
start to form complexes with siChi3l1 from 1:10, and mainly at
1:25 N/P ratio (Fig. 8b), thus we chose dNP2-siRNA complex
with 1:25 N/P ratio for further experiments. The dNP2-siChi3l1
complex size was measured by Nano particle size analyzer which
shows the size of the complex is increasing as the N/P ratio
(Fig. 8c). The molecular complex of 1:25 indicates around 300
nm. To conﬁrm the knockdown efﬁciency of the complexes, we
used Chi3l1-overexpressed HEK293T cells. The knockdown efﬁ-
ciency of dNP2-siChi3l1 complex or Lipofectamine-mediated
siChi3l1 delivery was compared at the mRNA (Fig. 8d) and
protein levels (Fig. 8e). dNP2-mediated siChi3l1 delivery sig-
niﬁcantly suppressed Chi3l1 expression dose dependently and the
level of suppression at 250 ng siRNA at 1:25 N/P ratio was
comparable to Lipo-siChi3l1 positive control. The siRNA com-
plex of dNP2-siChi3l1 and dNP2-siEGFP was intranasally
administered to C57BL/6 mice at day 0, and in vivo Chi3l1
knockdown efﬁciency was evaluated by RT-PCR. 2.5 μg of
siChi3l1 delivery by 70 μg of dNP2-HA2 peptide at 1:25 N/P ratio
showed signiﬁcant reduction of Chi3l1 mRNA expression in the
lung at day 1. Maximum silencing of Chi3l1 expression was noted
at day 2 and the level of Chi3l1 started to restore from day 3
(Fig. 8f). Chi3l1 protein was signiﬁcantly reduced from day 2 and
was sustained until day 3 (Fig. 8g, h). Both mRNA and protein
level of Chi3l1 in the lung was reduced by dNP2-siChi3l1 in dose
dependent manner (Supplementary Fig. 6a, b), however there was
no signiﬁcant effect observed by free siChi3l1 or free dNP2-HA2
peptide (Supplementary Fig. 6c) suggesting dNP2-HA2 peptide
truly enables siChi3l1 delivery into lungs via intranasal route and
knockdown target gene expression. Next, we determined the
functional activity of dNP-siChi3l1 in Th1 differentiation. FACS-
sorted WT naïve CD4 T cells were differentiated into Th1 cells
with dNP2-siChi3l1 or dNP2-siEGFP for 5 days. IFNγ- and
TNFα-producing cells were analyzed by ﬂow cytometry (Fig. 8i,
j). From 100 ng to 250 ng, dNP2-siChi3l1 resulted in signiﬁcantly
increased IFNγ-producing and TNFα-producing cells compared
to a dNP2-siEGFP-treated group. The increase of IFNγ mRNA
level by dNP2-siChi3l1 has correlation with signiﬁcantly decrease
of Chi3l1 mRNA level in Th1 cells (Fig. 8k). We conﬁrmed there
was no effect of equivalent dose of free siChi3l1 treatment in Th1
differentiation (Supplementary Fig. 7) suggesting critical role of
dNP2-HA2 for delivery of siRNA into T cells. These studies
collectively elicit that siRNA targeting Chi3l1 could be delivered
into T cells by dNP2-HA2 peptide and strengthened Th1 differ-
entiation and enhanced effector cytokine production by activated
CD8 T cells which would be a novel strategy to modulate T cell
immunity.
dNP2-siChi3l1 treatment suppresses pulmonary metastasis.
Finally, we investigated the in vivo efﬁciency of dNP2-siChi3l1
treatment in the regulation of melanoma lung metastasis. 14 days
after intravenous injection of 5 × 105 B16F10 melanoma cells into
WT mice, lung tissues were harvested and analyzed. 2.5 μg con-
trol siEGFP and siChi3l1 complexed with 70 μg dNP2-HA pep-
tide at 1:25 N/P ratio were intranasally administered twice per day
for every other day from day 0 to day 14 (Fig. 9a). Metastatic
melanoma colonies on the lung surface were observed (Fig. 9b)
and counted. There was a signiﬁcant reduction of number of
metastatic pleural colonies (Fig. 9c) and relative size of melanoma
colony (Fig. 9d) in the lung by dNP2-siChi3l1 treatment
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compared to dNP2-siEGFP-treated group. Histological analysis of
sectioned slides revealed that inﬁltrated tumors around blood
vessels were signiﬁcantly decreased in dNP2-siChi3l1 mice
(Fig. 9e). In addition, increased inﬁltrated IFNγ-producing CD4
T cells and Granzyme B-producing CD8 T cells were noted in the
lungs by dNP2-siChi3l1 (Fig. 9f, g). The protein level of intra-
cellular T-bet in both IFNγ-producing CD4 and CD8 T cells was
signiﬁcantly higher by dNP2-siChi3l1 treatment than the mice
with dNP2-siEGFP treatment (Fig. 9h). However, no difference
was noted in NK1.1 positive NK cells and NK1.1-CD4-CD8− cells
on IFNγ or Granzyme B expression by dNP2-siChi3l1 treatment
(Supplementary Fig. 8) suggesting peptide-siRNA complex
treatment speciﬁcally inﬂuences T cell functions. Consistent with
the RNA-sequencing data and RT-PCR results, dNP2-siChi3l1-
treated mice showed increased gene expression of anti-tumor
immunity molecules CTSE, TRAIL, IFNγ, T-bet, Perforin, and
Granzyme B, while the levels of Th1-inhibitory molecules such as
Twist1 and SOCS1 were signiﬁcantly down-regulated (Fig. 9i).
Free siChi3l1 treatment without dNP2-HA2 peptide does not
effect on melanoma lung metastasis and cytokine productions by
T cells (Supplementary Fig. 9) suggesting dNP2-HA2 complex is
critical for inhibition of metastasis. Furthermore, when we started
to treat dNP2-siChi3l1 intranasally at 2 days after intravenous
tumor injection as a therapeutic scheme, it also still signiﬁcantly
decreased the number of tumor colonies in the lung with
increased expression of IFNγ and TNFα expressing CD4 and
CD8 T cells suggesting it could inhibit tumor growth in the lung
as a therapeutic agent (Supplementary Fig. 10). Collectively, these
data suggest that dNP2-siChi3l1 is an effective and a novel siRNA
complex agent signiﬁcantly enhances anti-tumor immunity of
Th1 and CTL responses to inhibit tumor metastasis or growth in
the lung.
Discussion
Chitinase-like protein is an evolutionarily conserved protein in
mammals and does not show enzymatic activity4,5, while chit-
inase is an enzymatic defense system against pathogens in lower
organisms23,24. In mammals, Chi3l1, BRP-39, and YKL-40 are
expressed by cells including macrophages, chondrocytes, and
synovial cells and are involved in inﬂammation and tissue
remodeling6,25. Biological and physiological studies have shown
that macrophage expression of Ym-1 is highly induced by IL-4
and STAT6, which are recognized as M2 macrophage markers,
and induced Ym-1 promotes Th2 cytokine production and airway
inﬂammation7,8,17,26. In addition, Ym-1/2 induce γδ T-cell-
mediated neutrophil migration and IL-17 production against
nematode infection in mice9. Since no human homologs of Ym-1/
a b c
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2 are identiﬁed, the application of these Ym-1/2 ﬁndings in actual
human diseases could be signiﬁcantly limited. On the other hand,
Chi3l1, highly homologous to Ym-1/2, is expressed both in
human and rodent species. Importantly, the dysregulated
expression of Chi3l1 is also signiﬁcantly associated with many of
human diseases including asthma and various tumors. In recent
studies using transgenic or KO mice of Chi3l1 in various animal
models of lung diseases showed an essential role of Chi3l1 in the
pathogenesis of inﬂammation and tissue remodeling6,10,11,27,28.
Chi3l1 expression is highly increased in Th2 inﬂammatory con-
ditions induced by OVA/Alum and house dust mite (HDM), and
IL-13 transgenic mice6. Chi3l1 KO mice show reduced Th2
inﬂammation, and overexpression of YKL-40 reverses this phe-
notype6,29. In addition, IL-13 production by T cells and Th2
inﬂammation in lung-speciﬁc overexpression of IL-1830 are sig-
niﬁcantly reduced by Chi3l1 KO, however, IFNγ production by
T cells and Perforin, Granzyme B levels are signiﬁcantly increased
by Chi3l1 deﬁciency14. Although these studies identiﬁed Chi3l1
as a signiﬁcant immune modulator, the immune regulatory
function of Chi3l1 especially in T cells has not been characterized.
Here, we demonstrate that Chi3l1 is expressed in activated T cells
and Th2 cells, then regulates Th1 and Th2 differentiation through
increased IFNγ signaling. The genetic and chemical ablation of
Chi3l1 in T cells signiﬁcantly enhances Th1 and CTL responses
and inhibits tumor growth and lung metastasis. Our studies also
suggest that Chi3l1 regulation of T cell response is a critical event
in the pathogenesis of inﬂammatory and tissue remodeling and
tumor growth and progression in which the expression of Chi3l1
is dysregulated.
Previous studies revealed that IL-13Rα2 mediates the
Chi3l1 signaling and various effector function of Chi3l1 as a
putative receptor31. Exogenous Chi3l1 physically interacts with
IL-13Rα2, and recombinant Chi3l1 treatment enhances Erk/Akt
phosphorylation and β-catenin nuclear translocation in
THP1 cells. TMEM219 is reported to be another component of
the Chi3l1-IL-13Rα2 complex that physically binds to IL-
13Rα232. TMEM219 deﬁciency dampens the function of the
Chi3l1-IL-13Rα2 axis. However, we did not observe any effect of
recombinant mouse Chi3l1 (rmChi3l1) treatment on Th1 or Th2
differentiation in vitro, while treatment of rmChi3l1 signiﬁcantly
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reduces pro-inﬂammatory cytokine production in LPS-stimulated
peritoneal macrophages (Supplementary Fig. 11). In addition, IL-
13Rα2 mRNA was not detected in T cells with a signiﬁcant
phenotype onto dNP2-siChi3l1 treatment, suggesting an alter-
native biological mechanism of Chi3l1 in regulation of T cell
differentiation and activity. Recently Chi3l1 was reported as
localized in the cytosol and the nucleus, which could promote
monocyte-derived DC maturation33. We also speculate a possi-
bility that intracellular Chi3l1 could be able to regulate T cell
functions through more direct interaction with the molecules
working at the levels of cytosol or nucleus. Based on RNA-
sequencing analysis in our study, Twist1 is proposed as a target
molecule regulated by Chi3l1. Twist1 is a member of the basic
helix-loop-helix family and has been studied as a negative reg-
ulator of Th1 differentiation by suppression of IFNγ production
and T-bet and Runx3 functions34,35. In addition, Twist1 induces
SOCS1, which inhibits STAT1 phosphorylation to regulate the
IFNγ signaling pathway34. Thus, it is reasonable to speculate that
the decreased expression of Twist1 in the Chi3l1-deﬁcient
Th1 cells could be responsible for the increased IFNγ signaling
and related effector functions of T cells. In turn, increased IFNγ
signaling in Chi3l1 KO T cells shows more potent tumor-killing
activity with increased tumoricidal expression of molecules such
as CTSE, TRAIL, and Granzyme B. Previously, IFNγ has been
shown to increase the expression of ctse36 and trail37, which
contribute to tumor clearance in mice37–39. In addition, IFNγ also
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analyzed by intracellular cytokine staining. % of IFNγ+, % of Foxp3+, and MFI of Granzyme B was represented as scattered graph. g, h IFNγ producing NK
cells IFNγ producing non-lymphocytic population, and Granzyme B expression in IFNγ+ NK cells and non-lymphocytic population in the lung was analyzed.
% of IFNγ+, and MFI of Granzyme B was represented as scattered graph. i mRNA expression of genes related to cytotoxicity and Th1 effector functions was
analyzed by quantitative RT-PCR. Each gene expression level was normalized to β-actin. j Cytotoxicity of WT and Chi3l1 KO CD8 T cells against B16F10
target cells at indicated E:T ratios. k NK cell activity was represented as tumor killing activity of WT and Chi3l1 KO NK cells against to B16F10 target cells at
indicated E:T ratios. Data are mean± SD of three sets of independent experiments and each dot in graphs represent an individual mouse. n.s., not
signiﬁcant; *p< 0.05, **p< 0.01, ***p< 0.001 (two-tailed Student’s t-test)
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was reported to induce the expression of T-bet, which promotes
Perforin and Granzyme B expression in CD8 T cells40,41. How-
ever, we did not observe signiﬁcant functional differences in
Chi3l1 KO NK cells compared to WT NK cells in tumor-killing
activity or effector molecule expression in vitro and in vivo. As
presumably mRNA expression of Twist1 was signiﬁcantly lower
in NK cells than T cells, no difference was noted in the expression
of Twist1, T-bet, IFNγ, Granzyme B, and Perforin between WT
and Chi3l1 KO NK cells (Supplementary Fig. 12). These studies
further suggest that T cells are potentially major drivers of IFNγ
and other cytotoxic gene expression associated with anti-tumor
activity in the absence of Chi3l1. The exact molecular mechanism
of Chi31l in the expression of Twist1 and other genes need to be
further deﬁned in the future studies.
Chi3l1 was discovered in mouse breast cancer cells and has
been studied regarding tumors and inﬂammatory dis-
eases6,10,11,27,28. Chi3l1 is elevated in patients with a variety of
tumors, and recent studies have suggested that Chi3l1 promotes
cancers by enhancing cell proliferation, angiogenesis, etc28,42–44.
In addition, recent studies have shown that Chi3l1 that is induced
by the Semaphorin7A-β1 integrin signaling pathway contributes
to establishment of a metastatic microenvironment in the lung10,
and RIG-like Helicase activation reduces Chi3l1 expression,
which results in suppression of tumor progression in the lung11.
More recently, it was reported that Chi3l1 by ﬁbroblast enhances
migration and growth of breast cancer, and knockdown of Chi3l1
by shRNA increases T cell population and IFNy, TNFα expres-
sion45. Here, we added a novel regulatory function for intrinsic
Chi3l1 in anti-tumor T cell immunity in pulmonary metastasis
through functional regulation of Th1 cells and CTL activity. Thus,
these ﬁndings further suggest that Chi3l1 is an important ther-
apeutic target for treating tumors with dysregulated expression of
Chi3l1. Recently, IL-4 and Th2 inﬂammation was shown to
promote B16F10 melanoma metastasis15. Since Chi3l1 deﬁciency
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Fig. 7 Chi3l1 deletion in T cell inhibits pulmonary metastasis with increase of Th1 and CTL. a Genotyping PCR to conﬁrm CD4 speciﬁc deletion of Chi3l1 in
the mice. b Representative lung image from B16F10 melanoma injected WT and CD4-Chi3l1 KO mice. Scale bar, 2 mm c Number of pleural colonies in each
lung was counted. Data are mean± SEM of three sets of independent experiments and each dot in graphs represent an individual mouse. d Histology of
lung sections by H&E staining. Scale bar, 200m (e, f) IFNγ and/or TNFα producing CD4 T cells and CD8 T cells in the lung was analyzed by intracellular
cytokine staining. % of IFNγ+, % of TNFα+, and % of TNFα+IFNγ+ was represented as scattered graph. g, h IFNγ and/or TNFα producing NK cells, and non-
lymphocytic populations (NK1.1-CD4-CD8-) in the lung was analyzed by intracellular cytokine staining. % of IFNγ+, % of TNFα+, and % of TNFα+IFNγ+ was
represented as scattered graph. i mRNA expression of genes related to cytotoxicity and Th1 effector functions was analyzed by quantitative RT-PCR. Each
gene expression level was normalized to β-actin. Data are mean± SD of three sets of independent experiments and each dot in graphs represent an
individual mouse. n.s., not signiﬁcant; *p< 0.05, **p< 0.01, ***p< 0.001 (two-tailed Student’s t-test)
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reduced IL-4 production in Th2 cells while increasing IFNγ
expression in Th1 and CD8 T cells, targeting Chi3l1 could pro-
vide prominent anti-tumor effect by driving Th1 response while
suppressing the activity of tumor-promoting Th2 cells. In addi-
tion, dNP2-siChi3l1 treatment did not inhibit proliferation of
melanoma cells (Supplementary Fig. 13), suggesting that its
in vivo inhibitory effects on lung metastasis were mainly due to
the enhanced anti-tumor immunity, not by inducing direct tumor
cell death or suppressing proliferation of tumor cells.
Recently, cancer immunotherapy has been highlighted and
clinically validated for many cancers which enhances tumor-
killing T cell functions including immune checkpoint blockade
such as anti-PD-1 and anti-CTLA-4 antibodies, engineered T cell
therapy utilizing chimeric antigen receptors (CAR), and cancer
vaccines, etc46–50. Although cancer immunotherapy has been
emerging as an important addition to conventional therapies, still
there have been reported side effects or limitations of current
approaches to have autoimmune responses in signiﬁcant popu-
lations of patients or less effective due to individual variabilities of
tumor antigens47,49,51. Although we do not know whether Chi3l1
is implicated in the regulation of immune checkpoint molecules
such as PD-1 in the T cells, it is intriguing to speculate that Chi3l1
could complement the immunotherapy against the tumors that
do not respond to current immunotherapy or other approaches.
Based on Chi3l1 KO mouse phenotypes in the B16F10 melanoma
lung metastasis model, we developed a novel tumor treatment
agent based on siRNA and cell-penetrating peptide (CPP) com-
plexes. Previously, we identiﬁed and reported novel human-
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Fig. 8 Targeted inhibition of Chi3l1 by dNP2-siChi3l1 complex enhances effector cytokine production in Th1 and CD8 T cells. a Schematic diagram of the
complex formation of dNP2-HA2 peptide and Chi3l1 siRNA (siChi3l1) at indicated N/P ratios. b Gel retardation assay of dNP2-siChi3l1 complex. c The size
of free siRNA, free peptide, and dNP2-siRNA complexes were measured by Nano particle size analyzer. d Dose dependent reduction of Chi3l1 mRNA
expression by dNP2-siChi3l1 complex at 1:25 N/P ratio. e Chi3l1 protein level in culture supernatants were measured by ELISA. f Chi3l1 mRNA in the lung
after intranasal administration of dNP2-siEGFP or dNP2-siChi3l1 complex at 1:25 N/P ratio. Chi3l1 mRNA normalized to β-actin, and presented as relative to
expression at day 0. g Chi3l1 protein level in the lung was analyzed by Western blotting. Chi3l1 protein relative to expression at day 0. h Densitometric
values of band intensity was calculated by normalization to the value of β-actin, then the value was represented as relative to the value at day 0. Statistical
signiﬁcance of dNP2-siChi3l1 treated group was analyzed to dNP2-siEGFP treated group on each day. i FACS-sorted WT naïve CD4 T cells were
differentiated into Th1 cells and WT naïve CD8 T cells were activated by plate-bound anti-CD3 and anti-CD28 antibodies with IL-2 for 5 days with
indicated concentrations of dNP2-siEGFP or dNP2-siChi3l1 complexes. IFNγ and TNFα expression were analyzed by ﬂow cytometry. j % of TNFα+IFNγ+
cells were represented as bar graph. k Chi3l1 and IFNγ mRNA expression in dNP2-siChi3l1 treated Th1 cells. Each gene expression level was normalized to
β-actin, and represented as fold change to those of WT Th1 cell. Data are presented as mean± SD of three sets of independent experiments (n= 6). n.s.,
not signiﬁcant; *p< 0.05, **p< 0.01, ***p< 0.001 (two-tailed Student’s t-test)
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derived CPPs such as LPIN352, 2pIL-1αNLS53 and their appli-
cation potentials54. Recently, we identiﬁed another human-
derived CPP, dNP2 that efﬁciently escapes blood vessels and
localizes into resident cells in tissues differently from other CPPs
such as TAT or Hph-120. In addition, we showed it could be
efﬁciently delivered into lymphocytes including T, B, and NK
cells which are hardly transfected cells21. Here we utilized dNP2
peptide for effective siRNA delivery targeting Chi3l1 in tumor
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Fig. 9 In vivo administration of dNP2-siChi3l1 complex inhibits pulmonary metastasis with enhanced Th1 and CTL effector molecules. a Experimental
scheme of dNP2-siRNA complex treatment in pulmonary melanoma metastasis model. b Representative lung image of dNP2-siEGFP and dNP2-siChi3l1-
treated mice. Scale bar, 2 mm c Number of pleural colonies in each lung was counted. Data are mean± SEM of three sets of independent experiments and
each dot in graphs represent an individual mouse. d Relative total tumor area in the lung was measured by Image J software 1.48 v. e Histology of lung
sections by H&E staining, and inﬁltrated tumor region was measured by Image J software 1.48 v. Scale bar, 200m f, g IFNγ producing CD4 and CD8 T cells,
and Granzyme B expression level in IFNγ+ CD8 T cells in the lung was analyzed by intracellular staining. % of IFNγ+, and MFI of Granzyme B was
represented as scattered graph. h Intracellular T-bet expression level in CD4+IFNγ+ and CD8+IFNγ+ population. MFI was represented as scattered graph. i
mRNA expression of genes related to cytotoxicity and Th1 effector functions was analyzed by quantitative RT-PCR. Each gene expression level was
normalized to β-actin. Data are mean± SD of three sets of independent experiments and each dot in graphs represent an individual mouse. n.s., not
signiﬁcant; *p< 0.05, **p< 0.01, ***p< 0.001 (two-tailed Student’s t-test)
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lung metastasis. We demonstrated that intranasal delivery of the
siRNA with dNP2-CPP signiﬁcantly enhanced in vivo Th1 and
CTL activity with increased effector molecules in the lung but not
in other peripheral tissues (Supplementary Fig. 4), that efﬁciently
reduced lung metastasis of B16F10 melanoma cells. We also
preliminary attempted subcutaneous injection of B16F10 cells
that we still found signiﬁcantly increased tumor-inﬁltrating IFNγ
and/or TNFα producing CD4 and CD8 T cells although tumor
size was not reduced (Supplementary Fig. 14). As a further study,
we will more investigate antigen speciﬁc solid tumor model such
as EG-7-OVA versus OT-II TcR transgenic background CD4-
Chi3l1 KO mice. We also speculate there would be synergistic
function of increased Th1 immunity with macrophages in vivo
because dNP2-siChi3l1 could enhance IL-12 or IL-6 production
in LPS-stimulated macrophages in vitro (Supplementary Fig. 15).
Collectively, our observation suggests that siRNA complex
methodology with dNP2-HA2 peptide could be a novel approach
and an efﬁcient way of siRNA delivery to T cells and intervene
Chi3l1 expression for controlling tumor growth and progression.
In summary, we ﬁrstly revealed the function of an evolutionally
conserved chitinase-like protein, Chi3l1, in T cell adaptive
immunity. We suggest that Chi3l1 negatively regulates Th1 and
CTL functions and dNP2-siChi3l1 complex could be an alter-
native cancer immunotherapy approach for lung metastasis to
enhance Th1 and CTL functions but decrease of Th2. The
application and potency against various cancers will be further
investigated with combination of PD-1 antibody.
Methods
Mice. All mice used in this study were 6-week-old to 8-weeks-old mice on C57BL/
6 J background. Chi3l1 KO, and Chi3l1 ﬂoxed mice were originally generated and
kindly provided by Jack A. Elias. All mice were housed and maintained in a speciﬁc
pathogen-free facility. All mice were bred in controlled conditions of temperature
(21± 1 °C), humidity (50± 5%), and 12 h light/dark cycle with regular chow
(PicoLab Rodent Diet) and autoclaved water. Two-to-twelve mice that were used in
individual experiments were assigned randomly to the experimental groups. Also,
both sex of mice was also randomly assigned to the experimental groups.
Experiment and data analysis was performed without exclusion criteria. Blinding
was impossible in most of animal experiments. All animal protocols used in this
study were approved by the Animal Experimentation Ethics Committee. Experi-
ments were performed according to the guidelines of the Institutional Animal Care
and Use Committees.
In vitro T cell activation and differentiation. WT and Chi3l1 KO naïve CD4
T cells were isolated using mouse CD4+CD25−CD62L+ T Cell Isolation Kit II
(Miltenyi Biotec, 130-093-227, 130-104-453) according to the manufacturer’s
protocols. Purity was around 95%. Fluorochrome-labeled CD4+CD25
−CD62LhighCD44low naïve CD4 T cells and CD8+CD25−CD62LhighCD44low naïve
CD8 T cells were sorted by FACS Aria cell sorter (BD Biosciences, Franklin Lakes,
NJ). Purity was around 98%. Puriﬁed naïve CD4 and CD8 T cells were activated by
2 μg/mL plate-bound anti-CD3 (BD, 145-2C11) and anti-CD28 (BD, 37.51) anti-
bodies and differentiated by exposure to the following cytokines for 3 or 5 days:
media only for Th0; IL-2 (50 U/mL, Peprotech) for CTL; IL-12 (0.2 ng/mL, BD
Biosciences), IL-2 (50 U/mL), and anti-IL-4 antibody (5 μg/mL, BD Biosciences,
11B11) for Th1; IL-4 (30 ng/mL, BD Biosciences), IL-2 (50 U/mL), and anti-IFNγ
antibody (5 μg/mL, BD Biosciences, XMG1.2) for Th2; and TGF-β (0.5 ng/mL,
R&D Systems), IL-6 (30 ng/mL, BD Biosciences), IL-23 (20 ng/mL, BD Bios-
ciences), IL-1β (20 ng/mL, R&D Systems), anti-IFNγ (5 μg/mL), and anti-IL-4 (5
μg/mL) antibodies for Th17. For measuring IL-4 expression in the Th2 subset, Th2
cells were harvested at day 5 and further reactivated by plate-bound anti-CD3
antibody for 24 h. In some experiments, the indicated concentration of rmChi3l1
protein or IFNγ-neutralizing antibody or the indicated amount of dNP2-siEGFP or
dNP2-siChi3l1 was added to Th1- or CTL-skewing conditions. IL-2, IFNγ, IL-4,
and IL-17 were measured in culture supernatants by ELISA (eBioscience).
In vitro macrophage activation. Peritoneal macrophages from WT and Chi3l1
KO mice were obtained by the peritoneal lavage. Macrophages stimulated by 10 ng/
mL of LPS (O55:B5, sigma L2880) for 12 h with 250 ng of dNP2-siChi3l1 or 100 ng
of rmChi3l1 treatment. After LPS stimulation, culture supernatant was analyzed by
IL-6 and IL-12 ELISA following manufacturers instruction.
Flow cytometry. To measure cell proliferation, sorted WT and Chi3l1 KO naïve
CD4 T cells were stained with CFSE (0.75 μM, Invitrogen) for 10 min at 37 °C and
washed with complete RPMI media. CFSE-labeled cells were stimulated with plate-
bound anti-CD3 and anti-CD28 antibodies for 3 days. Dividing cells were analyzed
by ﬂow cytometry, following staining with anti-mouse CD4−PerCP-Cy5.5 anti-
bodies (1:1000 diluted, eBioscience, 45-0042-82). To determine intracellular cyto-
kine levels, cells were restimulated with eBioscience Cell Stimulation Cocktail (plus
protein transport inhibitors) for 4 h and stained with anti-mouse CD4-PerCP-
Cy5.5 or CD8−PerCP-Cy5.5 (1:1000 diluted, eBioscience, 45-0081-82) for 15 min.
Cells were further ﬁxed, permeabilized, and stained with anti-mouse IFNγ-FITC
(1:500 diluted, eBioscience, 11-7311-82), IL-4-PE (1:200, Biolegend, 504103) or
TNFα-PE (1:500 diluted, eBioscience, 12-7321-82), and IL-17-APC (1:500 diluted,
eBioscience, 17-7177-81) for CD4 T cells or IFNγ-APC (1:500 diluted, eBioscience,
17-7311-81), TNFα-PE (1:500 diluted), Granzyme B-FITC (1:200 diluted,
eBioscience, 11-8898-80) for CD8 T cells. Cells were analyzed by ﬂow cytometry.
For the pulmonary melanoma metastasis model, puriﬁed lymphocytes were resti-
mulated with eBioscience Cell Stimulation Cocktail (plus protein transport inhi-
bitors) for 4 h and stained with anti-mouse CD4-APC-Cy7 (1:200 diluted, BD,
561830), CD8-PerCP-Cy5.5 (1:500, diluted), and NK1.1-PE (1:500 diluted, Biole-
gend, 108707) or NK1.1-PE-Cy7 (1:500 diluted, Biolegend, PK136), or anti-mouse
CD4-APC-Cy7, CD8-PerCP-Cy5.5, and CD45-PE-cy7 (1:500 diluted, Biolegend,
30-F11) for 30 min. Cells were ﬁxed, permeabilized, and stained with anti-mouse
IFNγ-APC (1:500 diluted), Granzyme B-FITC (1:200 diluted), and T-bet-PE-cy7
(1:100 diluted, eBioscience, 25-5825-80), Foxp3-PE (1:400 diluted, eBioscience, 12-
5773-80) or anti-mouse IFNγ-APC, Granzyme B-FITC, and TNFα-PE (1:500
diluted) and analyzed by ﬂow cytometry. Data analysis was performed without
exclusion criteria.
Western blotting. Enriched naïve CD4 T cells were skewed to Th0, Th1, and Th2
helper T cells for 3 or 5 days and lysed with RIPA buffer (Cell Signaling Tech-
nology) in the presence of HALT inhibitor (Thermo Fisher Scientiﬁc) on ice for 30
min. Protein amounts in lysates were determined by Pierce BCA protein assay kit
(Thermo Fisher Scientiﬁc). After SDS-PAGE, proteins were transferred onto PVDF
membranes (Bio-Rad). Membranes were blocked with 5% skim milk in Tris-
buffered saline containing 0.1% Tween-20. After blocking, membranes were
incubated with primary antibody (listed below) for overnight at 4 °C. Membranes
were incubated with secondary antibody (listed below) for 1 h at RT. Washed
membranes were analyzed with EZ-Western Lumi Pico or Femto reagent (DoGen).
Band intensity was measured by Fusion-Solo, and gated band intensities from
acquired images were analyzed by Fusion-capt advance (Vilber Lourmat). Mouse
anti-Chi3l1 antibody was from R&D Systems (1:1000 diluted, MAB2649), and
mouse p-Erk (1:1000 diluted, #4377S), p-Akt (1:1000 diluted, #4060S), pSTAT1
(1:1000 diluted, #7649), pSTAT4 (1:1000 diluted, 4134S), pSTAT6 (1:1000 diluted,
#9361 P), tSTAT1 (1:1000 diluted, #9172 P), tSTAT4 (1:1000 diluted, 2653S), and
tSTAT6 (1:1000 diluted, #9362 P) antibodies and HRP-conjugated anti-rabbit
(1:20000 diluted, #7074) were from Cell Signaling Technology. HRP-conjugated
anti-rat (1:10000 diluted, 405405) antibody was from Biolegend. Raw western
blotting images are presented in Supplementary Fig 16.
Quantitative RT-PCR. Total RNA from in vitro differentiated CD4 T cells, CD8
T cells, and separated lung lymphocytes were isolated with RNeasy Mini kits (Qiagen)
following the manufacturer’s protocol. Lung tissue was disrupted by a homogenizer
with TRIzol (Thermo Fisher Scientiﬁc), and total RNA was extracted. cDNA was
synthesized with ReverTra Ace qPCR RT master mix (Toyobo). RT-PCR was per-
formed on a Bio-Rad CFX Connect RT-PCR detection system using iQ SYBR Green
Supermix (Bio-Rad). Primer sequences used are listed in Supplementary Table 1.
RNA-sequencing. Total RNA was isolated from WT and Chi3l1 KO naïve and
Th1 cells using TRIzol reagent (Invitrogen). RNA quality was assessed by Agilent
2100 bioanalyzer using RNA 6000 Nano Chips (Agilent Technologies, Amstelveen,
Netherlands). RNA quantiﬁcation was performed using an ND-2000 spectro-
photometer (Thermo Fisher Scientiﬁc). For control and test RNAs, library con-
struction was performed using SENSE mRNA-Seq Library Prep Kits (Lexogen, Inc.,
Austria) according to the manufacturer’s instructions. Brieﬂy, 2 μg of total RNA is
prepared and incubated with magnetic beads decorated with oligo-dT, then all
other RNAs except mRNA were removed by washing. Library production is
initiated by random hybridization of starter/stopper heterodimers to the poly(A)
RNA still bound to the magnetic beads. These starter/stopper heterodimers contain
Illumina-compatible linker sequences. A single-tube reverse transcription and
ligation reaction extends the starter to the next hybridized heterodimer, where the
newly-synthesized cDNA insert is ligated to the stopper. Second-strand synthesis is
performed to release the library from the beads, and the library is then ampliﬁed.
Barcodes were introduced when the library was ampliﬁed. High-throughput
sequencing was performed as paired-end 100 sequencing using a HiSeq 2000
instrument (Illumina, Inc., USA). mRNA-Seq reads were mapped using the
TopHat software tool to obtain an alignment ﬁle. Differentially expressed genes
were determined based on counts from unique and multiple alignments using Edge
R within R version 3.2.2 (R development Core Team, 2011) using BIO-
CONDUCTOR version 3.0. The alignment ﬁle was used for assembling transcripts,
estimating abundances, and detecting differential expression of genes or isoforms
using cufﬂinks. FPKM (fragments per kilo base of exon per million fragments)
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method used to determine expression levels of gene regions. A global normalization
method was used for comparisons between samples. Gene classiﬁcation was based
on searches performed by DAVID (http://david.abcc.ncifcrf.gov/).
dNP2-siRNA complex formation. To determine optimal conditions for forming
cell-permeable peptide-siRNA complexes, EGFP or Chi3l1 siRNA (Bioneer) was
mixed with dNP2-HA2 peptide (Genscript, KIKKVKKKGRKGSKIKKVKKKGRK-
GLFGAIAGFIENGWEGMIDG) which is a combined sequence of a cell-
penetrating peptide dNP2 and endosomal escape sequence of HA222 at various N/P
ratios (the number of amine groups in dNP2-HA2 peptide to the number of
phosphate groups in siRNA) and incubated for 30 min at RT in the dark. The size
of dNP2-siRNA complex was measured by Nano particle size analyzer (K-one).
Gel retardation assay. 1.5 μg of Chi3l1 siRNA (Bioneer) was mixed with dNP2-
HA2 peptide at various N/P ratios and incubated for 30 min at RT in the dark.
After incubation, complexes were mixed with DNA loading dye, and gel electro-
phoresis was performed on 2% agarose gel for 20 min.
Pulmonary melanoma metastasis model. The mouse melanoma cell line
(B16F10) established from C57BL6/J mouse melanoma was purchased from ATCC
(CRL-6475). B16F10 cells are maintained in complete DMEM at 37 °C. After cul-
turing to 90% conﬂuence in complete DMEM, cells were harvested, adjusted to 106
cells/mL in pre-warmed PBS, and 5 × 105 cells were i.v. injected into C57BL6/J,
Chi3l1 KO, CD4-speciﬁc Chi3l1 KO, and RAG KO mice. Mycoplasma con-
tamination was checked before the injection. RAG KO mice had transferred in vitro
differentiated WT or Chi3l1 KO Th1/CTL by i.v. injection at 5 days after melanoma
injection. At day 14, mice were sacriﬁced, and the numbers of melanoma colonies
visualized as black dots on the lung surface were counted. For histological analysis,
parafﬁn blocks of lung tissues were deparafﬁnized and stained by hematoxylin and
eosin. Tumor sizes in lung tissue were measured by Image J software 1.48 v. Lung
tissues were mechanically chopped and incubated in Ca2+-containing and Mg2
+-containing DPBS with collagenase D (1mg/mL, Roche) for 30min at 37 °C. In
experiment for Supplementary Fig. 3, tumor region and non-tumor region were
mechanically separated, and digested by collagenase D. Enzymatic digestions were
stopped with 0.5M EDTA solution. Digested cells were ﬁltered by 40-μm cell
strainer, and RBCs were lysed with Ack buffer. In addition, to conﬁrm systemic
effect of Chi3l1 KO or dNP2-siChi3l1 treatment, splenocytes and inguinal lymph
node cells were analyzed. Lung lymphocyte cells were enriched by Percoll gradients,
and the cells were analyzed by ﬂow cytometry and quantitative RT-PCR.
Subcutaneous tumor growth model. 1 × 105 of B16F10 melanoma cells were s.c.
injected into C57BL6/J, CD4-Chi3l1 KO mice. The size of tumor was checked for
every 2 days. At day 18, mice were sacriﬁced, and the tumor tissue was dissected for
further experiment. Tumor sizes were measured by caliper. Tumor tissues were
mechanically chopped and incubated in Ca2+-containing and Mg2+-containing DPBS
with collagenase D (1mg/mL, Roche) for 30min at 37 °C. Enzymatic digestions were
stopped with 0.5M EDTA solution. Digested cells were ﬁltered by 40-μm cell strainer,
and RBCs were lysed with Ack buffer. Tumor inﬁltrated lymphocyte cells were
enriched by Percoll gradients, and the cells were analyzed by ﬂow cytometry.
In vitro cytotoxicity assay. B16F10 melanoma cells were seeded into 96-well
plates in 100 μL media. After WT and Chi3l1 KO FACS-sorted CD8 T cells were
activated with plate-bound anti-CD3 and anti-CD28 antibodies for 4 h, the cells
were added to wells containing B16F10 cells at different effector to target (E:T)
ratio. For NK cell cytotoxicity assay, FACS-sorted NK cells were activated with
1000 U/mL IL-2 for 10 days, then the cells were re-activated with plate-bound anti-
NKG2D antibody (eBioscience, 16-5872-82) for 4 h. The pre-activated NK cells
were added to wells containing B16F10 cells at different effector to target (E:T)
ratio. Remained live cells were stained with CCK-8 and the percent CTL and NK
cell activity was calculated as relative percentage to the OD value of B16F10 only
control.
In vitro dNP2-siRNA transfection. To express Chi3l1 in HEK293T/17 cells
(ATCC, CRL-11268), cells were transfected with a cloned Chi3l1-overexpression
vector using Lipofectamine 2000 (Invitrogen). Transfection followed the manu-
facturer’s protocol. To make dNP2-siChi3l1 complex, indicated concentration of
siChi3l1 was mixed with dNP2-HA2 peptide. Mixture was incubated for 30 min at
RT in the dark. dNP2-siChi3l1 was added independently, and media were replaced
6 h later. Transfected cells were incubated for 2 days, and media and cells were
harvested. Chi3l1 levels in culture media were determined by ELISA (R&D), and
Chi3l1 mRNA in transfected cells was quantiﬁed by RT-PCR.
In vivo dNP2-siRNA transfection. 1.25 or 2.5 μg of Chi3l1 siRNA (Bioneer) or
EGFP siRNA (Bioneer) was incubated with 35 or 70 μg dNP2-HA2 peptide for 30
min at RT, in the dark. Free siRNA or Peptide-siRNA complexes were intranasally
administered to mice, which were sacriﬁced every 24 h for 3 days. Lung tissue was
disrupted in T-PER Tissue Protein Extraction Reagent (Thermo Fisher Scientiﬁc)
for protein lysates or in TRIzol for RNA extraction. Chi3l1 protein in the lung was
measured by Chi3l1 ELISA kit (R&D Systems). In the lung metastasis model, 5 ×
105 B16F10 cells were intravenously injected to WT mice, and then 2.5 μg of
siRNA + 70 μg of dNP2-HA2 peptide complex was intranasally administered to
anesthetized mice with zoletil + Rompun for twice per day with 10 h interval for
every other day until day 14. At 14 days after melanoma injection, mice were
sacriﬁced and analyzed.
Statistical analysis. All data were analyzed by two-tailed Student’s t-test using
Prism5 (GraphPad). P-values less than 0.05 were considered statistically signiﬁcant.
Data availability. The total RNA sequencing data have been deposited in the GEO
database under the accession code GSE105056.The authors declare that all the
other the data supporting the ﬁndings of this study are available within the article
and its Supplementary Information Files, or from the corresponding authors on
reasonable request.
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